Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
6 hedge funds and large institutions have $4.51M invested in Hepion Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 3 → 6 (+3)
48% less capital invested
Capital invested by funds: $8.61M → $4.51M (-$4.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.99M |
| 2 |
Barclays
London,
United Kingdom
|
+$497K |
| 3 |
Morgan Stanley
New York
|
+$497K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
RFG Advisory
Birmingham,
Alabama
|
-$65K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$46K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$46K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$30K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
26
Acrospire Investment Management
Chicago,
Illinois
| – | -$29K | – | – |
|
|
BRWA
27
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$46K | – | – |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$46K | – | – |
|
|
EWA
29
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
| – | -$19K | – | – |
|
30
Goldman Sachs
New York
| – | -$23K | – | – |
|
|
RA
31
RFG Advisory
Birmingham,
Alabama
| – | -$65K | – | – |
|
32
SEI Investments
Oaks,
Pennsylvania
| – | -$1K | – | – |
|
|
TDC
33
Thompson Davis & Co
Richmond,
Virginia
| – | -$5K | – | – |
|
|
VKH
34
Virtu KCG Holdings
New York
| – | -$30K | – | – |
|
HEPA Hedge Fund Activity: Q2 2017 in Review
6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2017, worth a combined $4.51M — down 48% from $8.61M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HEPA positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.99M. The largest seller was RFG Advisory, cutting an estimated $65K.
- 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2017, up from 3 in Q1 2017.
- Funds reported $4.51M of Hepion Pharmaceuticals stock for Q2 2017, down 48% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q2 2017 and 0 closed out, a net change of +3 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2017 was Anson Funds Management, an estimated $1.99M added.
- The largest Hepion Pharmaceuticals seller in Q2 2017 was RFG Advisory, an estimated $65K sold.
Based on aggregated 13F filings for Q2 2017.